These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1361106)

  • 1. Oncogene expression in follicular neoplasms of the thyroid.
    Auguste LJ; Masood S; Westerband A; Belluco C; Valderamma E; Attie J
    Am J Surg; 1992 Dec; 164(6):592-3. PubMed ID: 1361106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of thyrotrophin receptor gene in thyroid carcinoma is associated with a good prognosis.
    Shi Y; Zou M; Farid NR
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):269-74. PubMed ID: 8222289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Follicular neoplasms of the thyroid in men older than 50 years of age. A DNA flow cytometric study.
    Hruban RH; Huvos AG; Traganos F; Reuter V; Lieberman PH; Melamed MR
    Am J Clin Pathol; 1990 Nov; 94(5):527-32. PubMed ID: 2239819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of ras oncogene product P21 in thyroid tumors: an immunohistochemical study].
    Gui K
    Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):140-2, 12. PubMed ID: 2163739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential oncogenic expression in thyroid follicular and Hürthle cell carcinomas.
    Masood S; Auguste LJ; Westerband A; Belluco C; Valderama E; Attie J
    Am J Surg; 1993 Oct; 166(4):366-8. PubMed ID: 8214294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
    Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
    Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PAX8-PPAR gamma 1 rearrangements in both follicular thyroid carcinomas and adenomas.
    Marques AR; Espadinha C; Catarino AL; Moniz S; Pereira T; Sobrinho LG; Leite V
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3947-52. PubMed ID: 12161538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression, amplification and rearrangement of c-myc gene in human thyroid carcinoma].
    Yang Y
    Zhonghua Yi Xue Za Zhi; 1991 Jun; 71(6):304-6, 22. PubMed ID: 1667490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA methylation profiling of well-differentiated thyroid cancer uncovers markers of recurrence free survival.
    Mancikova V; Buj R; Castelblanco E; Inglada-Pérez L; Diez A; de Cubas AA; Curras-Freixes M; Maravall FX; Mauricio D; Matias-Guiu X; Puig-Domingo M; Capel I; Bella MR; Lerma E; Castella E; Reverter JL; Peinado MÁ; Jorda M; Robledo M
    Int J Cancer; 2014 Aug; 135(3):598-610. PubMed ID: 24382797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence by in situ hybridization that c-erbB-2 proto-oncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas.
    Pääkkö P; Nuorva K; Kamel D; Soini Y
    Am J Respir Cell Mol Biol; 1992 Sep; 7(3):325-34. PubMed ID: 1355655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers for discrimination of benign and malignant follicular thyroid tumors.
    Fryknäs M; Wickenberg-Bolin U; Göransson H; Gustafsson MG; Foukakis T; Lee JJ; Landegren U; Höög A; Larsson C; Grimelius L; Wallin G; Pettersson U; Isaksson A
    Tumour Biol; 2006; 27(4):211-20. PubMed ID: 16675914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
    Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
    Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARgamma staining as a surrogate for PAX8/PPARgamma fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value.
    Sahin M; Allard BL; Yates M; Powell JG; Wang XL; Hay ID; Zhao Y; Goellner JR; Sebo TJ; Grebe SK; Eberhardt NL; McIver B
    J Clin Endocrinol Metab; 2005 Jan; 90(1):463-8. PubMed ID: 15483076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA aneuploidy in follicular thyroid neoplasia.
    Cusick EL; Ewen SW; Krukowski ZH; Matheson NA
    Br J Surg; 1991 Jan; 78(1):94-6. PubMed ID: 1998875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the myc cellular proto-oncogene in human thyroid tissue.
    Yamashita S; Ong J; Fagin JA; Melmed S
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1170-3. PubMed ID: 3760117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-erbB-2 oncoprotein in different types of thyroid tumors: an immunohistochemical study.
    Gumurdulu D; Uguz A; Erdogan S; Tuncer I; Demircan O
    Endocr Res; 2003 Nov; 29(4):465-72. PubMed ID: 14682475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood group antigens in differentiated thyroid neoplasms.
    González-Cámpora R; García-Sanatana JA; Jordà i Heras MM; Salaverri CO; Vázquez-Ramírez FJ; Argueta-Manzano OE; Galera-Davidson H
    Arch Pathol Lab Med; 1998 Nov; 122(11):957-65. PubMed ID: 9822123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Pax-8, p53 and bcl-2 in human benign and malignant thyroid diseases.
    Puglisi F; Cesselli D; Damante G; Pellizzari L; Beltrami CA; Di Loreto C
    Anticancer Res; 2000; 20(1A):311-6. PubMed ID: 10769673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer.
    Sadasivan R; Morgan R; Jennings S; Austenfeld M; Van Veldhuizen P; Stephens R; Noble M
    J Urol; 1993 Jul; 150(1):126-31. PubMed ID: 7685420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.